Background: Over 80% of global deaths caused by cardiovascular disease (CVD) and diabetes (DM) occur in developing countries. The burden of non-communicable disease (NCDs) in South Asia is increasing rapidly.
INTRODUCTION
The prevalence of non-communicable diseases (NCDs) such as cardiovascular disease (CVD) and diabetes mellitus type 2 (DM) is increasing worldwide, especially in low and middle income countries(1) (LMICs). Ischaemic heart disease was the single biggest cause of disability adjusted life years in the global burden of disease study (2) with an estimated 31% of all worldwide deaths being due to CVD(3).
The south Asia region has a population of 1.7 billion people, which has tripled since 1950. Life I population is by far the largest, with three- (4) . Along with the global trend, the prevalence of CVD and DM in the region is expected to continue to increase in the coming years (5) . In South Asia, some of the main drivers for this expected rise are economic transition, urbanisation and lifestyle changes (6) . The burden of disease is shifting from infectious, maternal and childhood diseases to non-communicable diseases. This epidemiological transition has occurred rapidly and CVD, DM and their complications now contribute a significant burden of disease in these LMICs (7) . For example, in India CVDs are now the leading cause of death in men and women in both rural and urban areas (1, 8) . In addition, India is now the country with the second largest number of people living with diabetes at 65.1 million (second only to China at 98. 4 
million).
According to the World Bank(9), the south Asian region has been the fastest growing economic region in recent years. In 2015 the combined GDP of all countries in the region was US$ 2,689,862million. By far the largest economy in the region is India (2015 GDP US$ 2,088,841million). Other economies include Pakistan (US$ 271,050million), Bangladesh (US$ 195,079million), Sri Lanka (US$ 82,316million), Nepal (US$ 21,195million), Afghanistan (US$ 19,331million), Maldives (US$ 3,435million) and Bhutan (US$ 2,058million).
Chronic diseases have a significant health impact on individuals and their families. Analysis of NCDs in South Asia highlights that while the burden is currently greatest among affluent groups, many adverse risk factors are concentrated among the poor portending future increases amongst those with the least resources to manage their condition(10). The International Diabetes Foundation (IDF) estimated diabetes related health care expenditure in 2014 to be approximately US$6.9 billion in the South Asia region(11). With limited capacity within the public health system to effectively identify and manage CVD and DM, healthcare costs are usually borne as out of pocket expenditure by the individual and their families in this region, often with catastrophic financial consequences (12) (13) (14) .
Although some countries in the region are beginning to explore social insurance schemes to fund healthcare expenditure, there is limited existing evidence to inform policy makers of these costs(15). A few literature reviews have been conducted, exploring some relevant aspects of this issue. B CVD LMIC (16) found a wide variation in costs but little evidence from low income countries. Yesudi (17) of the costs of DM in India found medication to be a large proportion of costs with the burden falling heaviest on the poor and " (18) of the economic costs of DM in relation to levels of national GDP found direct costs to be generally higher than indirect costs, with these direct costs GDP N addressed the question of all relevant economic costs, focused specifically on the South Asian region.
The aim of this systematic review, was to estimate the costs of CVD and the costs of diabetes to individuals and society, in the LMICs of the South Asia region according to the World Bank definition(19) which includes Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka. This review sought to identify and collate data from peer-reviewed studies to address the question: What are the economic costs related to cardiovascular disease and the economic costs related to diabetes mellitus and their complications on society, the health sector, individuals and their families in South Asia?
METHODS
This review was undertaken according to the Centre for Reviews and Dissemination guidelines for systematic reviews and meta-analyses(20). A protocol was developed to plan the review which is available from the authors on request. The review is reported according to PRISMA guidelines(21).
Search Strategy
In April 2015 we searched the databases listed below for studies containing costs of CVD and DM in the countries of South Asia:
EconPapers ( The search strategy comprised subject headings and text words identified by the project team and known relevant papers for the search concepts CVD, DM, Costs and South Asia. The CVD search concept was adapted from a Cochrane CVD review(22). Table 1 illustrates some of the terms we used, however the full search strategy can be found in the appendices. The results of the electronic searches were stored and managed in an EndNote library. Relevant references, cited in the identified studies, were also included, as well as any relevant studies that the authors already had from previous work. We did not have the financial and human resources to contact study authors.
Insert Table 1 here
Inclusion criteria
Studies were considered as eligible for inclusion, if they related to the specified countries in the World Bank South Asia region and if they related to any aspects CVD DM.
Our aim was to obtain to the fullest extent possible, relevant costs related to CVD, DM and their complications. We used a broad definition of cost including all perspectives and elements of costs or economic impacts. Therefore, we included costs related to CVD or costs related to DM as incurred by service users and their families, service providers, governmental organisations and society. We included any types of costs regardless of any categorisation made by authors including: direct, indirect and/or intangible costs. Inclusion of studies was not restricted by specific participants or settings with the aim of capturing all relevant costs of CVD, relevant costs of DM and the complications of either disease. Study designs included in the review were randomised controlled trials (RCTs); observational studies; cost-of illness studies and systematic reviews.
We included all participants diagnosed with either DM or CVD (including ischaemic heart disease, stroke, hypertension and congestive heart failure) and their complications. We also included studies that included patients with co-morbid CVD and DM. In regard to costs of diabetes, our study aims were focused on type 2 DM. However, studies not clearly specifying which type of DM or combining results for both type 1 and 2 were included. We did not include studies exclusively looking at type 1 or gestational diabetes mellitus.
Exclusion criteria
We excluded studies if there was no full text publication available; if it was a conference abstract; if it was written in a language other than English, Hindi, Urdu or Bengali; and, if it included costs that did not relate to usual care in that setting at the time (e.g. only related to costs of a novel intervention). Cost-benefit, cost-effectiveness, cost-minimisation and cost-utility analyses were not completely excluded but reviewed separately to identify possible sources of cost data. Systematic reviews were included to ensure that any relevant studies included in other reviews were also identified in ours. The systematic review itself was not included in our analysis as this would have led to double counting of data.
Study Selection
Following implementation of these search strategies, the title and abstract of each identified study were reviewed by one author and the inclusion/exclusion criteria applied. The full text articles of the short-listed studies were then reviewed independently by two authors using an extraction form and quality checklist. The two sets of quality scores were then reviewed by both authors together and discrepancies discussed to agree a consensus score for each study. If the two reviewers were unable to reach consensus on the scoring, a third reviewer was asked to assess the relevant points in the study and adjudicate.
Data Extraction, Quality Scoring and Risk of Bias
We developed a data extraction tool and two of the study team (FG and HE) tested it on 5 studies before it was used to extract the relevant data from the reviewed studies. The tool can be found in the appendices. Only information available in the publication was used for assessing inclusion criteria, for data extraction, and for quality assessment.
A number of different quality checklists are available in relation to economic evaluation but there is currently no universally accepted checklist that was suitable for this review. Therefore we developed a quality assessment checklist for this study, based on a review of a number of existing checklists (20, (23) (24) (25) (26) (27) (28) (29) (30) . This checklist enabled an assessment of risk of bias to be undertaken using a scoring system across 38 quality criteria. These criteria covered a full description of; methods, context and economic study design; quantification of resources and costs; currency, price year and discounting; uncertainty and sensitivity analysis; and appropriate reporting of results and conclusion. We scored the NA hese criteria. The total score is presented as a percentage of the available scores for each study, thus we did not score studies down for non-applicable ratings. This assumes that each criterion carries equal weight in the overall score. We did not exclude studies for a poor quality score, however the score is presented in table 3 and should be considered in the interpretation of results.
Summary Measures
The vast majority of studies included in this review are cost of illness studies. We reported our findings in standard health economics terms (30) : medical direct costs (financial transactions for health services), non-medical costs (financial transactions for non-medical services e.g. transport), indirect costs (lost productivity) and intangible costs (disvalue to an individual such as pain or suffering). Most units of measurement are reported as mean annual cost per patient or mean annual cost per hospital admission. Once we extracted these costs from each included study, we converted them to US$ for the price year 2015 (using Purchasing Power Parity data from the IMF), in order to enable meaningful comparisons. This was done using an online cost converter (v1.5 accessed in May 2016) designed for this purpose and found at http://eppi.ioe.ac.uk/costconversion/ (31). We grouped our findings by disease and by the presence of complications to assist with further comparison. Where studies collected data over several years and had not been adjusted to one price year, we took the mid-year as the original price year for conversion.
As studies included in this review reported findings for different diseases, with a range of complications in a variety of settings, it was not possible for us to synthesise the data into a metaanalysis. The findings of this systematic review are therefore descriptive in nature.
Results
We identified 1,437 articles from our searches (after duplicates had been removed). Five of these came from reference lists of other systematic reviews. Of these, 1,366 were excluded after screening titles and abstracts as not meeting our inclusion criteria. Of the remaining 71 articles that were eligible for full text review, 42 were excluded (the reasons are listed in Fig. 1 ) which left 29 studies to be included in our review.
Insert Fig. 1 here Study Characteristics (see Table 2 ) The vast majority of the studies (n=27) were cost of illness studies. The two remaining studies were economic modelling studies(32, 33). Most studies assessed costs from the patient perspective (n=24) with the rest being from the societal perspective (n=5). An important gap in the evidence base is the lack of information from half of the countries, with only 4 out of the 8 South Asia countries contributing to included studies. The results will, to a degree, be Indo-centric as the majority of studies (n=23) provided data from India. The other three countries represented were Pakistan (n= 5), Bangladesh (n=1) and Nepal (n=1). Most studies were set in public or private hospitals (n=22; of which 8 were across multiple sites and 4 were outpatient departments only). Other settings included a district/region (n=3) and nationwide settings (n=4). Most studies were quite recent, only six studies had collected data before the year 2000.
Sample sizes within the cost of illness studies ranged from 150 to 383,000 individuals, with a median sample size of 400. Twenty studies included data for DM (type 2 (n=7) or not stated (n=13); with 11 of these DM studies including complications of the disease). Eleven studies included data for CVD, of which, some included participants with DM (n=2) and some related specifically to stroke (n=3), hypertension (n=2) and angina (n=1). Of the 23 studies that reported mean age of the sample, the range of means was 49 to 70 years old. Of the 24 studies that reported on the sex ratio of the sample, males were in the majority in 20 studies (% males pooled across 24 studies = 56%).
Sources of cost data were obtained from self-reporting (n=21), hospital records (n=9), national reference costs (n=5) and international reference costs (n=2) with some studies combining several sources. As the majority were cost of illness studies it is unsurprising that the vast majority of included studies reported direct medical costs (n=28). These were mainly costs for consultation fees, medicines, lab investigations, admission charges, bed fees, surgery costs, nursing charges and rehabilitation fees. A lesser proportion of studies included direct non-medical costs (n= 17) which were mostly transport and food costs. Fewer studies still included indirect costs (n=5) which were all estimates of loss of productivity. One study included intangible costs which estimated a willingness to pay value using a bidding method. The currencies that studies reported in were Indian rupees (n=20), US dollars (n=7), Pakistan Rupees (n=4), International dollars (n=2) and pounds sterling (n=1).
Seven studies were authored by researchers from the same WHO Collaborating Centre for Research in Chennai, India(34-40) and three studies were from a study group in Bangalore(41-43). The results from our quality checklist indicate that many studies failed to report substantial elements of their methods, therefore, poor internal validity is a risk for these studies.
Insert Table 2 here Risk of Bias within studies (see Table 2 ) Using our quality checklist, we identified scores for included studies that ranged between 40.9% and 89.1%. The median score was 71.0%. The distribution of scores for the 29 studies is represented in Fig. 2 . Seven studies had a quality score below 60%. Five studies had a quality score exceeding 80%. There were no obviously similar study characteristics between poorly scoring studies. There was a similar range of quality scores for studies that included participants with DM compared to studies for CVD. The studies with low quality scores were spread across all diseases and study types (see table  3 ).
Insert Figure 2 here
Annual economic costs of CVD per person (see Table 3 )
There were eleven studies that estimated economic costs for CVD in some of the countries of South Asia. One study from India(44) estimated the annual direct medical cost of managing hypertension on an outpatient basis as US$ 386. Another study from India(45) estimated the annual cost of all CVD care as US$ 563. When patients are admitted to hospital with CVD significant costs are incurred with a range of US$ 677 -1,523(33, 46, 47) per hospitalisation. Among the studies that estimated hospitalisation costs for CVD, the earlier studies tended to have lower costs than later studies (even after adjusting for price year). For the routine management of CVD, drug costs were estimated in four studies (44, 46, 48, 49) . For the management of hypertension the range of annual drug costs was US$ 79 -231(44, 46, 48) and for CVD (defined broadly) the drug costs were estimated to be US$ 1.14 per day, or US$ 415 per year(49).
Given that stroke care requires significant treatment and rehabilitation as an in-patient and that all three studies that captured costs for stroke care (Pakistan=1, India=2) sampled in-patients, it is not surprising that estimates of costs were some of the highest found in this review. The range of direct medical costs associated with each stroke(50-52) was US$ 3,890 -28,451, with the range of direct non-medical costs being US$ 357 -1,552. Along with direct costs, indirect costs for transport and home adaptations for stroke were also substantial; estimated at US$ 872 1,719 per hospitalisation(51, 52). Overall costs of each stroke from a societal perspective were estimated(51, 52) to be US$ 5,966 -32,927. Given that the included studies only captured post-stroke data for 6 or 12 months, the longer term cost to society is likely to be substantially more (particularly indirect costs).
From a societal perspective the direct and indirect costs of CVD are considerable. Direct medical costs for CVD were estimated(33) to be US$ 10.2 billion for India in 2004. This data was then projected for the years 2016 and 2021 as US$ 14.4 billion and US$ 16.6 billion respectively which suggests a significant rise, in line with the growth in both population and prevalence. The authors emphasise that this impact falls predominantly on the working age population. Another study(32) modelled the estimated indirect costs of loss of productivity to the economies of India, Pakistan and Bangladesh, from CVD in 2015, which were estimated to be US$ 1.96 billion, US$ 0.21 billion and US$ 0.14 billion respectively. Table 3 )
Annual economic costs of DM per person (see
There were eighteen studies that estimated costs for DM in some of the countries of South Asia. Estimated costs for DM differed in terms of the type of costs that were included. Where costs were limited to outpatient care(41-43, 53-55) a range of US$ 463 -951 was found for mean direct medical costs. In studies that disaggregated these totals further for sub-samples within their data, the range of costs increased. For instance one study(55) in India reported that patients that used a Government funded outpatient service (compared to a private outpatient service) had lower costs at US$ 212 and a different study(35) identified mean direct costs of US$ 1,046 for urban patients and US$ 655 for rural patients. When hospital admissions were included in direct medical costs the range of mean direct medical costs rose slightly to US$ 575 -1216(37, 43, 53, 56). However the largest direct medical costs reported by studies(40, 57, 58) were for DM patients with complications, which had a range of US$ 246 4,597. The studies(57, 58) reported that complications with lower costs (US$ 246 502) were nephropathy and peripheral vascular complications such as minor foot ulcers. Higher costs (US$ 2,087 4,597) related to severe foot ulcers, amputations and coronary events.
Similar patterns to direct medical costs were seen for direct non-medical costs; with lowest costs for DM patients seen in outpatients only(54, 55) (range US$ 12 21) with higher costs for those who were also admitted to hospital(53) (US$ 258) and a greater range for those with complications(34, 36, 39, 40) (cost per admission range US$ 50 470). A wide range of mean annual indirect costs were estimated by studies(39, 41, 43, 53-55) for DM and its complications which ranged from US$ 9 up to US$ 2,803.
One study(39) estimated intangible costs for DM, as a willingness to pay, using a bidding method. This study found that on average patients were willing to pay US$1,936 a year to stay well. However, there was a significant range when broken down by number of complications (US$ 1,452 for no complications to US$ 7,260 for >4 complications) and by HbA1c level (US$ 484 for HbA1c <7 to US$ 1,936 for HbA1c >9).
When combining costs to obtain an overall estimate, costs similarly varied. A number of studies(34, 36, 40) modelled 2 year expenditure estimates based on their data for total direct costs (medical and non-medical) which included data for serious complications of DM. The range of these 2 year costs were US$ 2,420 to US$ 40,331 (or annual costs of US$ 1,210 20,166). Estimates from studies that additionally included indirect costs (to direct costs) tended to have much lower estimates as they were outpatient only or mixed outpatient and inpatient samples with fewer complications and so attracted lower costs. The range of total annual (direct and indirect) costs for these studies(41, 43, 54, 55, 59) was US$ 483 2,637. The study (39) that estimated costs incorporating direct, indirect and intangible costs estimated annual total costs of US$ 2,048.
Insert table 3 here

Discussion
Our review found broadly similar estimates of annual direct medical costs per person in South Asia for routine management of CVD compared with routine management of DM, with costs of US$ 386 for hypertension, US$ 563 for CVD and US$ 463 951 for DM outpatient care and US$ 575 1216 for all DM care. Importantly, when complications (such as stroke, severe foot ulcers, amputations and coronary events) of these diseases occurred and required treatment, there was a substantial increase in costs. For severe complications of DM the direct medical costs rose to US$ 2,087 4,597. For the occurrence of each stroke, direct medical costs were estimated to be US$ 3,890 -28,451. These findings indicate that the financial burden of treating the complications of CVD and DM in South Asia form a significant proportion of the overall financial burden of these diseases. Total annual direct costs for CVD in India have been modelled at US$14.4 billion in 2016, which is set to increase to US$16.6 billion by 2020. An economic imperative therefore clearly exists for policy makers in South Asia to increase preventative approaches, both to decrease the incidence of DM and CVD and to increase early detection as well as provide access to evidence based treatments in order to reduce the prevalence of costly complications.
The economic burden of these considerable direct costs borne by the patient as out-of-pocket expenditure (and increasingly by social insurance schemes) in the region is compounded by the indirect costs to individuals and families. Our review has identified total annual costs (direct and indirect) of US$ 1,210 20,166 per person for DM and US$ 5,966 32,927 for each patient suffering a stroke. At the national level an estimate of total economic burden of DM in India was US$ 99.2 billion to US$148.2 billion. This economic burden at the societal level is set to grow considerably across South Asia as the rapid epidemiological transition is set to continue. The recent increases in rates of smoking amongst the young, sedentary lifestyles and the consumption of added sugars and processed carbohydrates are projected to continue, increasing the prevalence of CVD and DM(62, 63). The ability of countries in the region to address this rising burden will depend on their commitment to preventative economic and health policies such as taxation, education, food labelling and health promotion in schools(64, 65).
Insert Table 4 here
The quality checklist that we developed for this study provided a wide range of quality scores for the included studies in our review. Studies with higher quality scores (>70%) tended to be those using more sophisticated research methods such as macro-economic modelling, multi-country data collection or estimation of indirect or intangible costs. Conversely, cost of illness studies had a wide range of quality scores with some scoring very poorly. The findings from our quality checklist support the criticism of cost of illness studies, concerning their variable results and lack of reliability due to the heterogeneity of methods employed(66). In order to improve the value of cost of illness studies, researchers should ensure they employ a robust methodological approach and follow recognised reporting standards (such as the CHEERS statement(28)). The main limitations of studies were: the inadequate description of the study population and therefore uncertainty about their representativeness; a lack of categorisation into commonly used economic categories (direct medical, direct non-medical, indirect and intangible costs); the unit costs and the sources of cost data were often not stated; the quantity of resource utilisation was not usually reported separately to the cost data; the perspective taken for the study was not often specified; and there was a lack of clarity about who bore the payment for costs identified.
The time horizon for most studies was a single year. No studies presented longitudinal costs. Given the chronicity of CVD and DM this is an important consideration. As life expectancy increases across South Asia(19) patients can expect to live longer with these diseases with increasing risks of developing associated complications and therefore an escalation of related health care costs. It is unclear how accurate these annual estimates are for cumulative costs for patients and society over " CVD DM South Asia would be welcomed.
Limitations
There are several limitations to our review. Firstly, the results are dominated by studies from India.
No studies provided data for Sri Lanka, Maldives, Afghanistan and Bhutan so the findings cannot easily be generalised to the region as a whole. Secondly, we only reviewed published literature and therefore some relevant data in grey literature (including non-indexed regional journals) may have been missed, limiting the comprehensiveness of our review. Thirdly, we did not contact authors to obtain clarifying information, which may have enriched the included data and subsequent findings. Lastly, we did not exclude studies from our review based on a low quality score from our checklist, so the internal validity of some studies is questionable. However, we have presented the quality scores to allow readers to interpret results accordingly. We recognise the limitations of using a checklist scoring system to assess risk of bias and the fact that all criteria carried equal weight. Further research to explore weighting these criteria and to validate the scoring system could improve this tool.
Conclusion
This systematic review of the economic costs of CVD, DM and their associated complications in South Asia has identified significant costs to individuals and families who bear the brunt of this financial burden currently. Marked increases in costs have been identified when complications of these chronic diseases occur, underlining the importance of secondary prevention approaches in chronic disease management. This review has summarised the current available evidence. However, given the variable quality of cost of illness studies included, the findings of this review are tentative. Higher quality studies from every country across the region, especially those that include longitudinal costs, are required to establish more robust cost estimates. Hendriks ME, Kundu P, Boers AC, et al.
Step-by-step guideline for disease-specific costing studies in low-and middle-income countries: a mixed methodology. 
